Harris accepts CNN invitation to second debate, urges Trump to join
Sullivan expresses worry over escalating Israel-Lebanon tension, calls Hezbollah strike as justice served
Court gives 5 days for X to validate its Brazil legal representative
Climate activists cleared in UK of charges in rooftop protest at Sunak's estate
Turkey calls on West to take 'deterrent steps' against Israeli action
Fears grip ethnic minorities after deadly violence in Bangladesh
Tiny rainforest lizards leap into water and don’t come up when expected. Scientists now know why
Man smashes Ai Weiwei sculpture at Italy art show opening
Diddy faces public scrutiny over alleged sex crimes as questions arise about future of his music
Lizard on track halts Formula 1 practice in Singapore
TOKYO (Reuters) - Shares of Japan's Eisai tumbled 11% and were on track for their biggest one-day fall in three years on Monday, after the European Union's regulator rejected the drugmaker's Leqembi treatment for early Alzheimer's disease.
The EU drugs regulator last week said the risk of serious brain swelling did not outweigh the drug's small impact on slowing cognitive decline.
Both Eisai and partner Biogen have said they will seek re-examination of the recommendation, but did not disclose what information they would provide the regulator.
"Because EU approval was broadly expected, we consider this a very big negative surprise," Jefferies analyst Stephen Barker wrote in a note to clients.
"Rejection by the EU might also hurt Leqembi's image in the U.S. and Japan, potentially hurting sales in those markets as well."
Eliminating European Leqembi sales from estimates could mean an eventual cut of overall sales estimates by around 20% and reduce the "fair value" of Eisai shares about 1,000 yen each, Barker said.
Shares of Eisai fell 11% in morning trade in Tokyo to 5,890 yen and were on track for their biggest one-day fall since July 2021.
That came after shares of Biogen fell around 7% in U.S. trading on Friday.
The therapy, also known as lecanemab, is approved in the U.S., China, Hong Kong, Israel, Japan and South Korea, and would have been Europe's first drug to treat the neurodegenerative condition rather than its symptoms.
(Reporting by David Dolan; Editing by Edwina Gibbs)
